Stock listing
NASDAQ:PPCB Propanc Biopharma, Inc. Stock
Home listing (NASDAQ) of Propanc Biopharma, Inc.
Follow Propanc Biopharma, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PPCB
$1.84 USD -0.27 (-12.8%)
Close on Oct 30, 2026
- Day range
- $1.79 – $2.13 USDOct 30, 2026
- Volume
- 64,600 sharesOct 30, 2026
- Market cap
- $1.90M USDAt the close on Oct 30, 2026 · price × 1.03M shares outstanding
- 52-week range
- $1.79 – $319.88 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- $366,332 USDMedian day 1,926 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PPCB · Home | $1.84 USD | -0.27 (-12.8%) | 64,600 | $1.91 | $2.13 | $1.79 | $2.11 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · NASDAQ:PPCB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.84 | -0.27 | -12.8% | $1.91 | $2.13 | $1.79 | 64,600 | |
| $2.11 | 0.00 | 0.0% | $2.14 | $2.21 | $2.10 | 29,900 | |
| $2.11 | -0.32 | -13.2% | $2.46 | $2.50 | $2.09 | 90,500 | |
| $2.43 | +0.14 | +6.1% | $2.24 | $2.473 | $2.21 | 45,000 | |
| $2.29 | -0.51 | -18.2% | $3.00 | $3.012 | $2.21 | 103,800 | |
| $2.80 | +0.06 | +2.2% | $2.78 | $2.849 | $2.505 | 2,677 | |
| $2.74 | -0.414 | -13.1% | $2.882 | $2.969 | $2.74 | 2,077 | |
| $3.154 | -0.056 | -1.7% | $3.10 | $3.225 | $3.10 | 586 | |
| $3.21 | +0.04 | +1.3% | $3.077 | $3.332 | $3.077 | 1,114 | |
| $3.17 | -0.25 | -7.3% | $3.23 | $3.271 | $3.109 | 2,255 | |
| $3.42 | +0.005 | +0.1% | $3.505 | $4.025 | $3.25 | 20,521 | |
| $3.415 | -0.242 | -6.6% | $3.56 | $3.70 | $3.345 | 1,651 | |
| $3.657 | -0.468 | -11.3% | $4.279 | $4.614 | $3.65 | 8,257 | |
| $4.125 | -0.275 | -6.3% | $4.284 | $4.441 | $4.10 | 3,334 | |
| $4.40 | -0.457 | -9.4% | $4.887 | $4.899 | $4.25 | 1,956 | |
| $4.857 | +0.147 | +3.1% | $4.956 | $4.956 | $4.621 | 1,893 | |
| $4.71 | -0.277 | -5.6% | $4.974 | $4.986 | $4.61 | 1,947 | |
| $4.987 | +0.074 | +1.5% | $4.99 | $5.071 | $4.60 | 8,780 | |
| $4.913 | -0.087 | -1.7% | $4.83 | $5.30 | $4.83 | 1,878 | |
| $5.00 | -0.075 | -1.5% | $5.10 | $5.266 | $4.899 | 907 | |
| $5.075 | +0.065 | +1.3% | $5.059 | $5.30 | $5.00 | 720 | |
| $5.01 | +0.07 | +1.4% | $4.90 | $5.178 | $4.90 | 829 | |
| $4.94 | -0.183 | -3.6% | $5.16 | $5.215 | $4.714 | 1,314 | |
| $5.123 | -0.211 | -4.0% | $5.15 | $5.515 | $5.00 | 1,439 | |
| $5.334 | -0.969 | -15.4% | $6.15 | $6.228 | $5.178 | 4,216 | |
| $6.303 | +0.285 | +4.7% | $5.911 | $6.698 | $5.91 | 3,842 | |
| $6.018 | -0.262 | -4.2% | $6.30 | $6.667 | $5.60 | 1,923 | |
| $6.28 | -0.23 | -3.5% | $6.393 | $6.525 | $6.004 | 1,929 | |
| $6.51 | +0.213 | +3.4% | $6.469 | $6.845 | $6.376 | 4,246 | |
| $6.297 | +0.197 | +3.2% | $6.102 | $6.484 | $5.95 | 1,423 | |
| $6.10 | -0.20 | -3.2% | $6.63 | $6.655 | $6.029 | 1,599 | |
| $6.30 | -0.05 | -0.8% | $6.41 | $7.321 | $6.29 | 4,498 | |
| $6.35 | -1.85 | -22.6% | $8.48 | $8.599 | $6.253 | 11,030 | |
| $8.20 | -0.30 | -3.5% | $8.60 | $8.803 | $8.13 | 1,738 | |
| $8.50 | -0.71 | -7.7% | $9.00 | $9.106 | $8.283 | 2,809 | |
| $9.21 | -0.218 | -2.3% | $9.222 | $9.349 | $8.744 | 2,276 | |
| $9.428 | -0.472 | -4.8% | $9.734 | $9.762 | $9.36 | 1,283 | |
| $9.90 | -0.40 | -3.9% | $10.10 | $10.30 | $9.15 | 3,044 | |
| $10.30 | +0.20 | +2.0% | $10.20 | $10.40 | $9.914 | 1,737 | |
| $10.10 | -0.10 | -1.0% | $10.50 | $10.50 | $9.715 | 1,944 | |
| $10.20 | -0.10 | -1.0% | $10.30 | $10.35 | $9.697 | 3,437 | |
| $10.30 | -1.00 | -8.8% | $11.00 | $11.60 | $10.00 | 5,299 | |
| $11.30 | -2.20 | -16.3% | $12.70 | $12.75 | $11.10 | 6,232 | |
| $13.50 | 0.00 | 0.0% | $12.90 | $14.80 | $12.50 | 7,976 | |
| $13.50 | -8.80 | -39.5% | $19.30 | $19.40 | $13.10 | 40,569 | |
| $22.30 | +11.60 | +108.4% | $35.10 | $41.30 | $19.80 | 973,171 | |
| $10.70 | -0.60 | -5.3% | $11.19 | $11.20 | $10.70 | 92 | |
| $11.30 | -0.25 | -2.2% | $11.40 | $11.60 | $10.80 | 150 | |
| $11.55 | +0.75 | +6.9% | $11.00 | $11.90 | $10.80 | 230 | |
| $10.80 | -0.20 | -1.8% | $11.20 | $11.20 | $10.50 | 251 | |
| $11.00 | -0.40 | -3.5% | $11.30 | $11.80 | $11.00 | 208 | |
| $11.40 | -0.20 | -1.7% | $11.85 | $11.85 | $11.00 | 369 | |
| $11.60 | +0.10 | +0.9% | $11.20 | $11.94 | $11.00 | 331 | |
| $11.50 | -0.70 | -5.7% | $12.50 | $12.70 | $11.50 | 465 | |
| $12.20 | 0.00 | 0.0% | $12.10 | $12.90 | $12.00 | 394 | |
| $12.20 | +0.10 | +0.8% | $12.40 | $12.60 | $12.00 | 345 | |
| $12.10 | +0.40 | +3.4% | $12.30 | $12.60 | $11.70 | 390 | |
| $11.70 | +0.20 | +1.7% | $11.80 | $12.40 | $11.60 | 441 | |
| $11.50 | -0.50 | -4.2% | $12.00 | $12.38 | $10.65 | 836 | |
| $12.00 | -1.60 | -11.8% | $12.20 | $12.60 | $11.80 | 1,934 | |
| $13.60 | +1.80 | +15.3% | $12.50 | $16.00 | $11.00 | 12,348 | |
| $11.80 | +1.60 | +15.7% | $10.60 | $13.20 | $10.50 | 5,950 | |
| $10.20 | -0.30 | -2.9% | $11.00 | $11.00 | $9.776 | 476 | |
| $10.50 | +0.40 | +4.0% | $10.20 | $10.70 | $10.00 | 755 | |
| $10.10 | -0.30 | -2.9% | $10.70 | $10.80 | $9.50 | 393 | |
| $10.40 | +0.50 | +5.1% | $10.00 | $10.84 | $9.70 | 463 |
- Ticker
- NASDAQ:PPCB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news
Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
Oct 30, 2026
Closed $1.84 (-12.8%) on Oct 30, 2026
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
Oct 26, 2026
Closed $2.29 (-18.2%) on Oct 26, 2026
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
Oct 22, 2026
Closed $2.80 (+2.2%) on Oct 23, 2026
Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
Oct 16, 2026
Closed $3.42 (+0.1%) on Oct 16, 2026
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
Oct 14, 2026
Closed $3.66 (-11.3%) on Oct 14, 2026
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
Oct 7, 2026
Closed $4.99 (+1.5%) on Oct 7, 2026
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
Sep 29, 2026
Closed $5.12 (-4.0%) on Sep 29, 2026
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
Sep 22, 2026
Closed $6.51 (+3.4%) on Sep 22, 2026
Decks
Investor Presentation (April 2024)
Investor deck · 26 slides · Apr 10, 2024
Investor Presentation (February 2019)
Investor deck · 25 slides · Feb 12, 2019
Investor Presentation (September 2018)
Investor deck · 32 slides · Sep 7, 2018
Investor Presentation (June 2017)
Investor deck · 38 slides · Jun 1, 2017
Propanc Biopharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 47 in the last 12 months · 115 in all · newest Oct 30, 2026 · oldest 2019
- Decks
- 5 decks · latest Apr 10, 2024
Where Propanc Biopharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PPCB · Home listing · This page | NASDAQ | United States | USD |
| BOATS:PPCB | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Propanc Biopharma, Inc.